ABSTRACT
A potential risk factor for immunogenicity of a biotherapeutic is the low levels of host cell protein (HCP) impurities that remain in the product following the purification process. During process development, significant attention has been devoted to removing HCPs due to their potential safety risk. Samples from different purification steps of several monoclonal antibodies (mAbs) purified by one type of platform were evaluated for their residual Chinese Hamster Ovary (CHO) cell-derived HCP content. HCPs in both in-process (high levels of HCP) and highly purified (low levels of HCP) samples were identified and quantitated by proteomic analysis via mass spectrometry. The responses to HCPs were evaluated in an in vitro assay using PBMC from a population of healthy and disease state individuals. Results indicated that samples with up to 4000 ppm HCP content (levels 200 times greater than the drug substance) did not pose a higher immunogenicity risk than highly purified mAb samples. As an orthogonal method to predict immunogenicity risk, in silico algorithms that probe amino acid sequence for foreign epitope content were used to evaluate over 20 common HCPs (identified in the different mAb samples). Only a few HCPs were identified as high risk by the algorithms; however, the in vitro assay results indicated that the concentration of these HCPs from in-process biotherapeutic mAb samples was not sufficient to stimulate an immune response. This suggests that high levels of HCP in mAb biotherapeutics purified by this type of platform do not increase the potential risk of immunogenicity of these molecules. Insights from these studies can be applied to HCP control and risk assessment strategies.
Similar content being viewed by others
References
Bracewell DG, Francis R, Smales CM. The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control. Biotechnol Bioeng. 2015;112(9):1727–37.
de Zafra CL, Quarmby V, Francissen K, Vanderlaan M, Zhu-Shimoni J. Host cell proteins in biotechnology-derived products: A risk assessment framework. Biotechnol Bioeng. 2015;112(11):2284–91.
ICH (1999) ICH Harmonized Tripartite Guideline. Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Q6B.
Verthelyi D, Wang V. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS One. 2010;5(12), e15252.
Haile LA, Puig M, Kelley-Baker L, Verthelyi D. Detection of innate immune response modulating impurities in therapeutic proteins. PLoS One. 2015;10(4), e0125078.
Sharma B. Immunogenicity of therapeutic proteins. Part 2: impact of container closures. Biotechnol Adv. 2007;25(3):318–24.
Sharma B. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. Biotechnol Adv. 2007;25(3):325–31.
Sharma B. Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol Adv. 2007;25(3):310–7.
Wadhwa M et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res: an Off J Am Assoc Cancer Res. 1999;5(6):1353–61.
Kobiyama K et al. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines. 2013;1(3):278–92.
Schenauer MR, Flynn GC, Goetze AM. Profiling the effects of process changes on residual host cell proteins in biotherapeutics by mass spectrometry. Biotechnol Prog. 2013;29(4):951–7.
Gao SX et al. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol Bioeng. 2011;108(4):977–82.
Bailey-Kellogg C et al. CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production. Biotechnol Bioeng. 2014;111(11):2170–82.
Champion K, Madden H., Dougherty,J. and Shacter,E. (2005) Defining Your Product Profile and Maintaining Control Over It, Part 2 Challenges of Monitoring Host Cell Protein Impurities. Bioprocess International:52-57.
Ipsen’s partner Inspiration Biopharmaceuticals announces hold of phase III clinical trials evaluating IB1001 for the treatment and prevention of hemophilia B (2012) (http://www.ipsen.com/wp-content/uploads/2013/1003/PR_IB1001-Clinical-Hold_EN_1000.pdf).
Jaber A, Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal. 2007;43(4):1256–61.
Jaber A et al. The Rebif new formulation story: it’s not trials and error. Drugs R D. 2007;8(6):335–48.
Joubert MK et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012;287(30):25266–79.
Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. Classification and characterization of therapeutic antibody aggregates. J Biol Chem. 2011;286(28):25118–33.
Luo Q et al. Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions. J Biol Chem. 2011;286(28):25134–44.
Doneanu CE et al. Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry. MAbs. 2012;4(1):24–44.
Jawa V et al. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534–55.
Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M et al. Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. 2016; PLOS One (in press)
Geromanos SJ et al. The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS/MS. Proteomics. 2009;9(6):1683–95.
Silva JCGM, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Molecular & cellular proteomics : 144-56. Mol Cell Proteomics. 2006;5:144–56.
McMurry J et al. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis. 2005;85(1-2):95–105.
Moise L, Cousens L, Fueyo J, De Groot AS. Harnessing the power of genomics and immunoinformatics to produce improved vaccines. Expert Opin Drug Discovery. 2011;6(1):9–15.
De Groot AS et al. An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. AIDS Res Hum Retrovir. 1997;13(7):529–31.
Diamond B. Speculations on the immunogenicity of self proteins. Dev Biol. 2003;112:29–34.
Zhang Q et al. Comprehensive tracking of host cell proteins during monoclonal antibody purifications using mass spectrometry. MAbs. 2014;6(3):659–70.
Vanderlaan M, Sandoval,W., Liu,P., Nishihara, J.,Tsui,G., Lin,M., Gunawan F., Parker, S., Ming Wong,R., Low, J.,Wang,X.. Yang, J., Veeravalli K.,McKay,P.,Yu,C., O’Connell L., Tran,B.,Vij,R., Fong,C.,Francissen, K., Zhu-Shimoni, J. Quarmby,V and Krawitz,D. (2015) Hamster Phospholipase B-Like 2 (PLBL2): A Host-Cell Protein Impurity in Therapeutic Monoclonal Antibodies Derived from Chinese Hamster Ovary Cells Bioprocess International.
Ahmadi M et al. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res. 2015;32(4):1383–94.
Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinforma. 2007;8:238.
Moise L et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother. 2013;9(7):1577–86.
De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 2009;131(2):189–201.
van Beers MM, Bardor M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J. 2012;7(12):1473–84.
Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nature reviews. Immunology. 2007;7(3):179–90.
Acknowledgments
The authors wish to thank Helen Reynolds, Mark Fogg, Matthew Baker, and Gary Bembridge from Antitope Ltd for data generation and/or analysis. We thank Frances Terry and Annie De Groot from EpiVax for the critical review of the manuscript and their feedback, Linda Narhi and Dan Mytych for technical advice and reviewing the manuscript. Thanks to Chris Crowell and Ming Li for providing material and/or useful discussions. We thank Mark Kroenke for assistance with the in silico analysis.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(GIF 126 kb)
Rights and permissions
About this article
Cite this article
Jawa, V., Joubert, M.K., Zhang, Q. et al. Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics. AAPS J 18, 1439–1452 (2016). https://doi.org/10.1208/s12248-016-9948-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-016-9948-4